Lavipharm (FRA:BXA0) Total Receivables: €21.54 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:BXA0 Lavipharm SA FRA:BXA0
79 GF Score
Price €1.55
GF Value €1.03
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Lavipharm Total Receivables?

Lavipharm FRA:BXA0 +0.78% 79 Total Receivables is €21.54 Mil as of Dec. 2025. GuruFocus rates FRA:BXA0 with a GF Score™ of 79/100 and a GF Value™ of €1.03 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Lavipharm's Total Receivables for the quarter that ended in Dec. 2025 was €21.54 Mil.

Lavipharm Total Receivables Historical Data

* Premium members only.

The historical data trend for Lavipharm's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lavipharm Total Receivables Chart

Lavipharm Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only 13.26 17.13 21.70 15.15 21.54

Lavipharm Semi-Annual Data
Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.70 15.51 15.15 17.86 21.54
FRA:BXA0
79GF Score
Lavipharm SA FRA:BXA0
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lavipharm Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €21.54 Mil mean?
Lavipharm (FRA:BXA0) has a Total Receivables of €21.54 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lavipharm and its competitors.
Is Lavipharm's Total Receivables too high?
Lavipharm's current Total Receivables is €21.54 Mil. Overall, Lavipharm has a GF Score™ of 79/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lavipharm's Total Receivables compare to ZTS and UTHR?
Lavipharm's Total Receivables of €21.54 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Lavipharm and its competitors. Lavipharm's current Total Receivables is €21.54 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lavipharm stock overvalued right now?
Based on GuruFocus' analysis, Lavipharm (FRA:BXA0) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.03, compared to a current price of €1.55 — trading 50.5% above its estimated fair value. The current Total Receivables is €21.54 Mil. Lavipharm's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Lavipharm (FRA:BXA0), the current Total Receivables is €21.54 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lavipharm (FRA:BXA0) Overvalued in 2026?

Based on GuruFocus' analysis, Lavipharm stock appears to be overvalued. The current stock price of €1.55 is trading 50.5% above its estimated GF Value™ of €1.03. GuruFocus considers Lavipharm to be Significantly Overvalued.

Key valuation signals for FRA:BXA0:

  • Total Receivables: €21.54 Mil
  • GF Value™: €1.03 vs. price of €1.55 (50.5% above fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the FRA:BXA0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lavipharm Business Description

Other Exchanges LAVI:Greece
Address 12, Agias Marinas Street, PO Box 59, Paiania, GRC, 19002
Lavipharm SA develops, manufactures, markets, and distributes pharmaceutical, cosmetic, and consumer health products in Greece and internationally. The company's product portfolio includes safe and effective therapeutic solutions that meet consumers' needs for health and well-being. Its main product categories are Cardiology, Oncology, Urology, Neurology, Psychiatry, Chronic Pain, General Medicine, Self-Treatment, and Dermocosmetic care.
79GF Score

Get the complete analysis for FRA:BXA0

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.55
Price
€1.03
GF Value